Q-omics provides the consensus-scored CXXC4 profile across patient tissues and cancer cell-line models. CXXC4 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CXXC4 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, CXXC4 RNA expression shows 18,915 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where CXXC4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CXXC4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CXXC4 survival associations across molecular data types. CXXC4 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CXXC4 RNA expression–survival associations across cancer types. High CXXC4 expression shows unfavorable associations in KIRP and UVM, but favorable associations in KIRC, PAAD, LGG and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CXXC4 RNA expression.
This table summarizes CXXC4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CXXC4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CXXC4 shows lower tumor expression in THCA, KICH, LUSC and HNSC and higher tumor expression in KIRC and BRCA. The KIRC box plot shows higher CXXC4 RNA expression in tumor versus normal tissue (log2 FC = +0.905, t-test p < 0.001).
This table shows molecular features associated with CXXC4 in patient tissues and cancer cell lines. In patient samples, CXXC4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CXXC4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LUNG_SCLC.
